TY - JOUR
T1 - Effect of Low-Density Lipoprotein Apheresis for Nephrotic Idiopathic Membranous Nephropathy as Initial Induction Therapy
AU - Koshi-Ito, Eri
AU - Koike, Kiyomi
AU - Tanaka, Akihito
AU - Watanabe, Yu
AU - Kamegai, Naoki
AU - Shimogushi, Hiroya
AU - Shinjo, Hibiki
AU - Otsuka, Yasuhiro
AU - Inaguma, Daijo
AU - Takeda, Asami
N1 - Publisher Copyright:
© 2019 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Low-density lipoprotein apheresis (LDL-A) has been used for nephrotic syndrome (NS) caused by focal segmental glomerulosclerosis in Japan. Idiopathic membranous nephropathy (iMN) can also cause treatment-resistant NS. Therefore, we investigated the effect of LDL-A during initial induction for it. This retrospective, observational, and single-center study enrolled consecutive iMN patients who received steroids from March 2000 to May 2015. We compared data between 11 patients treated with LDL-A (LDL-A group) and 27 patients without (non-LDL-A group) at baseline and 4 and 8 weeks later. Reduction rate of proteinuria and increase rate of serum albumin in LDL-A group were significantly higher than the other after 4 weeks (P = 0.036 and 0.030) and 8 weeks (P = 0.030 and <0.001), respectively. There was no adverse event caused by LDL-A and immunosuppressant dose was not significantly different. In conclusion, LDL-A may be an effective choice for initial induction of nephrotic iMN.
AB - Low-density lipoprotein apheresis (LDL-A) has been used for nephrotic syndrome (NS) caused by focal segmental glomerulosclerosis in Japan. Idiopathic membranous nephropathy (iMN) can also cause treatment-resistant NS. Therefore, we investigated the effect of LDL-A during initial induction for it. This retrospective, observational, and single-center study enrolled consecutive iMN patients who received steroids from March 2000 to May 2015. We compared data between 11 patients treated with LDL-A (LDL-A group) and 27 patients without (non-LDL-A group) at baseline and 4 and 8 weeks later. Reduction rate of proteinuria and increase rate of serum albumin in LDL-A group were significantly higher than the other after 4 weeks (P = 0.036 and 0.030) and 8 weeks (P = 0.030 and <0.001), respectively. There was no adverse event caused by LDL-A and immunosuppressant dose was not significantly different. In conclusion, LDL-A may be an effective choice for initial induction of nephrotic iMN.
UR - http://www.scopus.com/inward/record.url?scp=85067421546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067421546&partnerID=8YFLogxK
U2 - 10.1111/1744-9987.12811
DO - 10.1111/1744-9987.12811
M3 - Article
C2 - 30993827
AN - SCOPUS:85067421546
SN - 1744-9979
VL - 23
SP - 575
EP - 583
JO - Therapeutic Apheresis and Dialysis
JF - Therapeutic Apheresis and Dialysis
IS - 6
ER -